Forward P/S Multiple: SI-BONE (SIBN)

SI-BONE, Inc. - graphic logo of issuer SIBN

A strategic focus on expert trainers and specialized sales agents ensures personnel stability for SI-BONE, Inc. (SIBN). The company's forward P/S visualizes the impact of this resource on share prices, where 4.90 describes the current status of the metric. The dominance of the iFuse system in the joint fixation niche expands market reach, while outsourcing simple blanks to external plants under internal quality control optimizes costs.

si-bone.com - SIBN Market Cap to Projected Revenue (period 07/04/2022 - 11/13/2026)

Summary analytical data breakdowns for SI-BONE Medical (SIBN)

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Fundamental company analysis:SIBN (SI-BONE)
Product sample of SI-BONE Medical

For SI-BONE, Inc., a developer of unique implants for minimally invasive surgery, the forward P/S serves as a tool for assessing market value relative to expected sales. This metric compares current market capitalization with projected revenue, allowing for the determination of the asset's overbought status. By analyzing the company's projected P/S, an investor can timely identify emotional price spikes. This ensures objective valuation control for a business that relies on the recognition of its products by the professional surgical community.

Who SI-BONE, Inc. competes with

Price-to-Projected Revenue Ratio Boston Scientific Corporation BSX|EW - Forward Price-to-Revenue Multiple|ResMed Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Insulet Inc.|ZBH: Forward P/S Multiple|Market Cap to Projected Revenue COO|ALGN (Align Technology) - Forward P/S Multiple|Globus Medical Inc (GMED) - Market Cap to Expected Sales Ratio|Forward P/S Multiple TMDX|Forward Price-to-Revenue Multiple Alphatec Corp ATEC|Forward P/S Multiple AORT (Artivion, Inc.)|Forward P/S Multiple enovis.com ENOV|IART - Price-to-Projected Revenue Ratio|ESTA: Price-to-Projected Revenue Ratio|BBNX (Beta Bionics Corp) - Forward Price-to-Revenue Multiple|IRADIMED Inc. - Forward Price to Sales|EMBC (Embecta Corp.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio tandemdiabetes.com TNDM|Price-to-Projected Revenue Ratio Axogen (AXGN)|Orthofix Medical (OFIX) - Projected Price to Revenue|Bioventus Corp - Forward Price-to-Revenue Multiple|Forward P/S Multiple OrthoPediatrics Corp KIDS|Treace Medical Concepts - Forward P/S Multiple|Market Cap to Expected Sales Ratio blade.com SRTA|Carlsmed (CARL) - Price-to-Projected Revenue Ratio|Future Price to Revenue RXST (RxSight Inc)|Price-to-Projected Revenue Ratio ClearPoint Neuro Inc.|Forward Price-to-Revenue Multiple Stereotaxis Corporation (STXS)|Forward P/S Multiple STIM|SGHT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Orchestra BioMed, Inc. OBIO|ANIK: Market Cap to Projected Revenue|NSPR: Forward Price-to-Revenue Multiple|Jin Medical International - Price to Expected Revenue Ratio|vivani.com (VANI) - Price-to-Projected Revenue Ratio|XTNT - Market Cap to Expected Sales Ratio|NMTC (NeuroOne Medical Technologies Corporation) - Forward P/S Multiple|Modular Med (MODD) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple MYO (Myomo, Inc)|Envoy Medical Inc (COCH) - Projected Price to Revenue|Forward P/S Multiple VVOS (Vivos Therapeutics)|envveno.com - Price-to-Projected Revenue Ratio|SINT - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Tenon Medical Inc.|ReWalk Robotics Ltd (LFWD) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue AMIX|IVF (INVO Fertility Inc) - Forward P/S Multiple|Market Cap to Future Revenue Ratio bonebiologics.com BBLG|Forward Price-to-Revenue Multiple AXNX (Axonics)|BIOL (BIOLASE Inc.) - Forward Price to Sales|Forward P/S Multiple DYNT (Dynatronics)|Market Cap to Expected Sales Ratio Paragon 28 Inc. (FNA)|INVO - Price-to-Projected Revenue Ratio